Biotech Startups
9,882 companies tagged Biotech, with their investors and founders.
QpexBio develops anti-infective drugs designed to overcome multidrug resistance, improving existing drug classes and discovering new ones for use in combination with known anti-infectives against drug-resistant bacteria. The company operates R&D laboratories in San Diego, California, working alongside Shionogi's research labs in Japan.
3 investors
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers. Its pipeline includes clinical and preclinical candidates aimed at KRAS mutations (including G12D and G12V) beyond those addressed by approved G12C inhibitors, alongside a RAS-partner discovery program using conformation-sensitive assays.
3 investors
Quanterix develops technology for highly sensitive detection of protein biomarkers using non-invasive sample types, aimed at early disease detection and prevention. The company serves the precision healthcare and life sciences research market with biomarker detection tools.
3 investors
Quantum-Si integrates biochemistry, chemistry, hardware, molecular biology, photonics, semiconductor chips, and software to develop solutions for medical research and healthcare. The company focuses on advancing diagnostic and research capabilities through hardware and software integration.
3 investors
QUiCKR develops rapid genetic modification quantification kits for cell and gene therapy R&D programs, analyzing structural variants, edits, and genome integrity to accelerate development timelines and reduce costs.
3 investors
Quilt provides a data platform for life sciences teams to organize, manage, and collaborate on scientific data stored in AWS. The platform consolidates data across multiple sources, enables AI-powered search, and maintains compliance with regulatory standards including HIPAA and GxP requirements.
3 investors
3 investors
Reach Industries builds a visual intelligence layer for science, combining AI, software, and hardware to support work in the life sciences. The company develops intelligent systems intended to augment human tasks such as research and problem-solving.
3 investors
San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.
3 investors
Recludix Pharma operates a drug discovery platform that combines custom DNA-encoded libraries (DELs), massively parallel structure-activity relationship analysis, structure-based design, and a family-wide SH2 domain screening panel. It applies this approach first to discover selective SH2 domain inhibitors for treating inflammatory diseases.
3 investors
Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas. This page profiles a member of its executive team.
3 investors
3 investors
Red Queen Bio builds an AI-powered biodefense system that rapidly designs and manufactures countermeasures against emerging biological threats, enabling faster defensive responses to evolving pathogenic risks.
3 investors
Redona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology. The company is led by experienced biotech executives with backgrounds in immunology, oncology, and translational medicine.
3 investors
Refeyn develops mass photometry instruments that measure the mass of individual biomolecules in solution without labels, enabling analysis of protein purity, interactions, and viral vector characterization for research and manufacturing applications.
3 investors
Regenosine develops regenerative medicine therapies for musculoskeletal and orthopedic conditions. The company leverages adenosine-based science to address inflammatory diseases and tissue healing.
3 investors
REGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.
3 investors
Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.
3 investors
Related Sciences assembles distributed teams of academic experts and industry veterans to conduct specialized drug discovery and research for biotech companies. The company operates a decentralized R&D model where leading scientists work collaboratively on targeted therapeutic programs.
3 investors
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.
3 investors
Replay develops gene therapies for patients with rare genetic diseases. It operates in the biotechnology and gene therapy sector.
3 investors
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder. Its lead candidate, luvesilocin (RE104), is a short-duration prodrug of 4-OH-DiPT that targets the serotonin 2A receptor.
3 investors
Rhizocore Technologies develops mycorrhizal fungal inoculum products to enhance plant growth, woodland restoration, and ecosystem resilience. The company serves forestry, agriculture, and ecosystem restoration sectors with biotech solutions for carbon-negative forest productivity.
3 investors
3 investors